<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestion xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionVersion>
        <isActive>true</isActive>
        <name>Hemolytic_Uremic_Syndrome_For_DeNovo_Initial_Section_C_Criteria_Q1</name>
        <optionSourceResponseValue>false</optionSourceResponseValue>
        <questionText>Either criteria 1 or 2 must be met. If eculizumab is withdrawn, we suggest the monitoring strategy noted below, and approval for one urgent dose will be provided in the event of relapse with further coverage requiring completion of Section D. If eculizumab is continued, approval is for 12 months, with annual reassessment required under Section E.</questionText>
        <status>Active</status>
        <versionNumber>1</versionNumber>
    </assessmentQuestionVersion>
    <dataType>TextBlock</dataType>
    <developerName>HUS_For_DeNovo_Initial_Section_C_Criteria_Q1</developerName>
    <name>HUS_For_DeNovo_Initial_Section_C_Criteria_Q1</name>
    <questionCategory>Demographic</questionCategory>
</AssessmentQuestion>
